Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
Colecalciferol
Stada Arzneimittel AG
A11CC; A11CC05
Colecalciferol
25000 international unit(s)
Oral solution
Vitamin D and analogues; colecalciferol
2017-11-24
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT FULTIUM-D 3 25000 IU ORAL SOLUTION cholecalciferol (vitamin D 3 ) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Fultium-D 3 is and what it is used for 2. What you need to know before you take Fultium-D 3 3. How to take Fultium-D 3 4. Possible side effects 5. How to store Fultium-D 3 6. Contents of the pack and other information 1. WHAT FULTIUM-D 3 IS AND WHAT IT IS USED FOR Fultium-D 3 contains the active ingredient cholecalciferol (vitamin D 3 ): Vitamin D 3 regulates the uptake and metabolism of calcium as well as the incorporation of calcium in bone tissue. Fultium-D 3 is used for initial treatment of symptomatic vitamin D deficiency in adults. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE FULTIUM-D 3 DO NOT TAKE FULTIUM-D 3 - if you are allergic to vitamin D or any of the other ingredients of this medicine (listed in section 6) - if you have high levels of vitamin D in your blood (hypervitaminosis D) - if you have high blood levels of calcium (hypercalcaemia) or high urine levels of calcium (hypercalciuria) - if you have kidney stones or serious kidney problems. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Fultium-D 3 - if you have kidney damage or disease. Your doctor will need to measure the levels of calcium in your blood or urine - if you are being treated for heart disease - if you have sarcoidosis (an immune system disorder which may affect your liver, lungs, skin or lymph nodes) - if you are already taking additio Preberite celoten dokument
Health Products Regulatory Authority 29 January 2021 CRN00C49H Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Vitamin D3 Internis 25 000 IU Oral Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION A 2.5 ml single-dose bottle containing 25 000 IU Cholecalciferol (equivalent to 625 micrograms vitamin D 3 ) For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Oral solution, in single-dose container. Pale yellow transparent, odourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Initial treatment of symptomatic vitamin D deficiency in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Recommended dose: One bottle (25 000 IU) weekly. After first month, lower doses may be considered, dependent upon desirable serum levels of 25-hydroxycolecalciferol (25(OH)D), the severity of the disease and the patient´s response to treatment. Alternatively, national posology recommendations in treatment of vitamin D deficiency can be followed. _Dosage in hepatic impairment_ No dose adjustment is required. _Dosage in renal impairment_ Fultium-D 3 should not be used in patients with severe renal impairment (see section 4.3). _Paediatric population_ Fultium-D 3 is not recommended in children and adolescents under 18 years of age Method of administration This medicine is taken orally. Patients should be advised to take Fultium-D 3 25 000 IU Oral Solution preferably with a meal (see section 5.2). The product should be shaken before use. Fultium-D 3 Oral Solution can be dispensed onto a spoon or mixed with a small amount of cold or lukewarm food or drink immediately prior to use. The whole portion should be consumed. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Hypervitaminosis D Nephrolithiasis Diseases or conditions resulting in hypercalcaemia and/or hypercalciuria Health Products Regulatory Authority 29 January 2021 CRN00C49H Page 2 of 5 Severe renal impairment 4.4 SPECIAL WARNINGS AND PRECAUTION Preberite celoten dokument